Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest update is out from NurExone Biologic ( (TSE:NRX) ).
NurExone Biologic Inc. has received a U.S. patent allowance for its proprietary exosome manufacturing process, enhancing its supply chain readiness and securing global market protection. This milestone, coupled with the acquisition of a GMP-grade Master Cell Bank, strengthens NurExone’s path towards clinical trials and commercial positioning, establishing a robust foundation for its clinical supply chain and future business-to-business supply of exosomes.
The most recent analyst rating on (TSE:NRX) stock is a Buy with a C$2.61 price target. To see the full list of analyst forecasts on NurExone Biologic stock, see the TSE:NRX Stock Forecast page.
More about NurExone Biologic
NurExone Biologic Inc. is a biotech company listed on the TSX Venture Exchange, OTCQB, and Frankfurt, focusing on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, targets acute spinal cord and optic nerve injuries, which are multi-billion-dollar markets. The company is advancing towards clinical trials in the U.S. and Europe and aims to offer quality exosomes and minimally invasive targeted delivery systems.
Average Trading Volume: 43,431
Technical Sentiment Signal: Buy
Current Market Cap: C$49.83M
Find detailed analytics on NRX stock on TipRanks’ Stock Analysis page.